You are here

Our science / Clinical Trials / Find a Trial / NCT00219609

Assessment Of Safety Of UK-390,957

Back to Search Print Save as PDF Bookmark Trial

NCT00219609

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Tucson, Arizona, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ejaculation
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029)
and will have met the diagnostic criteria for premature ejaculation as defined by
DSM-IV

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- No drug related serious adverse events

NCT00219609
Pfizer
Completed
Assessment Of Safety Of UK-390,957

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Ejaculation
Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
NCT00219635
Males
18+
Years
Multiple Sites
Ejaculation
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
NCT00143117
Males
18+
Years
Multiple Sites
Ejaculation
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
NCT00219583
Males
18+
Years
Multiple Sites
Ejaculation
Assessment Of Safety Of UK-390,957
NCT00219609
Males
18+
Years
Multiple Sites
Assessment Of Safety Of UK-390,957
A Phase 2 Multi-Center, Open Label Long-Term Extension Trial To Assess The Safety Of Oral Uk-390,957 Administered As Required In Adult Men With Premature Ejaculation
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
Not Provided
Interventional
Phase 2
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Ejaculation
Drug: UK-390,957
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1058
March 2006
March 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV

Exclusion Criteria:

  • No drug related serious adverse events
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Austria,   Canada,   Czech Republic,   France,   Germany,   Israel,   Italy,   Norway,   Poland,   Sweden,   Turkey,   United Kingdom,   United States
 
 
NCT00219609
A3871028
Not Provided
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now